Compare Eli Lilly And Co (LLY) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vistra Corp — how do they compare? Eli Lilly And Co trades at $1,173.02 (market cap $1.04T), while Vistra Corp trades at $160.84 (market cap $52.41B). The key difference: Eli Lilly And Co is far larger — about 19.8× Vistra Corp's market cap, and Vistra Corp is more actively traded (11,278,074 versus 3,064,878). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vistra Corp for 32 Days on average.
| LLY | VST | |
|---|---|---|
Market Cap | $1.04T | $52.41B |
Volume | 3,064,878 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $1.28K | $210.85 |
52-Week Low | $799.57 | $134.71 |
Typical Hold Time | 93 Days | 32 Days |
Enterprise Value | $1.09T | $74.34B |
Dividend Yield | 0.59% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Vistra Corp. (VST) trades at $160.84, down 3.53% over the past day, amid mixed quarterly earnings but strong analyst support. The stock shows a bullish technical trend with support at $152 and resistance at $164, while fundamentals reflect robust profitability with an 11.55% net income margin and 75.73% ROE. Recent developments include a $4.2 billion US loan to expand nuclear power output and a 20-year power supply agreement with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Outlook remains positive given Wall Street's consensus price target of $215.23, implying 34% upside, though risks include earnings volatility and high valuation multiples. Investment appeal hinges on execution of growth initiatives in nuclear and data center power markets, with institutional confidence underscored by Peter Thiel's significant stake.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
